Shares of HNI Corp. (NYSE:HNI) surged in the extended session Friday after the company boosted its earnings guidance for the second quarter and fiscal year 2016, driven by outstanding operational execution, material and operations productivity, and strong returns on prior investments
HNI said that it now expects to deliver second quarter 2016 non-GAAP net income in the range of $0.62 to $0.67 per diluted share on a sales decrease of 6% to 8% over the prior year quarter, representing an increase from the previously reported non-GAAP net income guidance range of $0.54 to $0.59 per diluted share on a sales decrease of 4% to 7% versus the same period the prior year
HNI now estimates full year 2016 non-GAAP earnings per diluted share to be between $2.70 and $2.90 on a sales decrease of 1% to 3% over the prior year, versus the prior guidance of non-GAAP earnings of $2.40 to $2.70 per diluted share on a sales decrease of 2% to 4% year-over-year
HNI stock closed at $46.94, down $0.29 (or -0.61%) on Friday.
HNI Corp. engages in the design, manufacture, and marketing of office furniture and hearth products primarily in the United States, Canada, China, Hong Kong, India, and Taiwan
Dynavax Technologies Corp. (Nasdaq:DVAX) said on Saturday that preliminary results from a pivotal Phase 3 trial showed that, with two doses over one month, its investigational adult hepatitis B vaccine HEPLISAV-B provided a significantly higher rate of seroprotection in participants with type 2 diabetes than Engerix-B®, an approved hepatitis B vaccine
According to Dynavax, HEPLISAV-B provided seroprotection in 90.0% of participants with diabetes versus 65.1% for Engerix-B in the study - a statistically significant difference of 24.9%.
Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease.
The U.S. Food and Drug Administration (FDA) has established December 15, 2016, as the Prescription Drug User Fee Act (PDUFA) action date for the HEPLISAV-B Biologics License Application.
DVAX shares finished Friday's trading session at $14.59, down $0.46 (or -3.06%)
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious diseases and oncology.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer